Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Drug-drug Interaction Study of SH229 Tablets and Daclatasvir Dihydrochloride Tablets in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03748745
Recruitment Status : Completed
First Posted : November 21, 2018
Last Update Posted : August 13, 2019
Sponsor:
Information provided by (Responsible Party):
Nanjing Sanhome Pharmaceutical, Co., Ltd.

Brief Summary:
The purpose of this study is to evaluate the drug-drug interaction of SH229 tablets and Daclatasvir dihydrochloride tablets. The study also evaluates the pharmacokinetics and tolerability of co-administration of SH229 tablets and Daclatasvir dihydrochloride tablets in healthy subjects. This study provides evidence for the designing of following clinical trial protocols.

Condition or disease Intervention/treatment Phase
Drug Interactions Drug: SH229 Drug: Daclatasvir dihydrochloride Phase 1

Detailed Description:
A total of 28 evaluable healthy subjects will be enrolled in this study. The dose of SH229 is 600 mg. The dose of Daclatasvir dihydrochloride is 60 mg.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single-center, Open-label, Steady-state Drug-drug Interaction Study of SH229 Tablets and Daclatasvir Dihydrochloride Tablets in Healthy Subjects
Actual Study Start Date : November 19, 2018
Actual Primary Completion Date : December 25, 2018
Actual Study Completion Date : December 25, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Drug Reactions

Arm Intervention/treatment
Experimental: Cohort A
SH229 (600 mg) once daily, Daclatasvir dihydrochloride (60 mg) once daily.
Drug: SH229
tablet, oral, 600 mg once daily for day 1 to day 14

Drug: Daclatasvir dihydrochloride
tablet, oral, 60 mg once daily for day 8 to day 14

Experimental: Cohort B
SH229 (600 mg) once daily, Daclatasvir dihydrochloride (60 mg) once daily.
Drug: SH229
tablet, oral, 600 mg once daily for day 8 to day 14

Drug: Daclatasvir dihydrochloride
tablet, oral, 60 mg once daily for day 1 to day 14




Primary Outcome Measures :
  1. Incidence of adverse events [ Time Frame: Up to 1 month after last dose ]
    Cohort A and Cohort B [Safety and tolerability]


Secondary Outcome Measures :
  1. Tmax, ss [ Time Frame: Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose ]
    Time of maximum observed concentration; safety and validity criteria

  2. Cmax, ss [ Time Frame: Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose ]
    Maximum observed concentration; safety and validity criteria

  3. Cmin, ss [ Time Frame: Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose ]
    Minimum observed concentration; safety and validity criteria

  4. t1/2, ss [ Time Frame: Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose ]
    Elimination half-life; safety and validity criteria

  5. AUC0-24, ss [ Time Frame: Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose ]
    Area under the concentration-time curve (AUC) from time 0 to 24 hours; safety and validity criteria

  6. AUC0-72, ss [ Time Frame: Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose ]
    Area under the concentration-time curve (AUC) from time 0 to 72 hours; safety and validity criteria

  7. AUC0-∞, ss [ Time Frame: Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose ]
    Area under the concentration-time curve (AUC) from time 0 to infinity; safety and validity criteria

  8. CL/F ss [ Time Frame: Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose ]
    Apparent clearance; safety and validity criteria

  9. DF [ Time Frame: Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose ]
    Degree of fluctuation; safety and validity criteria



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Sign the informed consent form before the study and fully understand the study content, process and possible adverse reactions;
  2. Be able to complete the study as required by the protocol;
  3. Subjects (including their partners) who are willing to voluntarily take effective contraceptive measures from screening to 6 months after the last dose. See the appendix for specific contraceptive measures;
  4. Male subjects aged 18-45 (including 18 and 45 years old);
  5. Male subjects who weigh no less than 50 kg and have a body mass index between 18 and 28 kg / m2 (including the threshold). Body mass index (BMI) = weight (kg) / height2 (m2);
  6. Physical examination and vital signs normal, or the abnormal signs have no clinical significance.

Exclusion Criteria:

  1. Smoke more than 5 cigarettes per day within three months prior to study;
  2. Subjects who are allergic to the study drugs or prone to allergies (Multiple drug and food allergies);
  3. Subjects with history of drug and/or alcohol abuse (14 units per week: 1 unit = 285 mL of beer, or 25 mL of hard liquor, or 100 mL of wine);
  4. Subjects with history of blood donation or massive blood loss (> 450 mL) within three months prior to screening;
  5. Subjects with dysphagia or have history of gastrointestinal disorders which affects study drug absorption;
  6. Subjects with any diseases that increase the risk of bleeding, such as hemorrhoids, acute gastritis, or gastric and duodenal ulcers;
  7. Use of any drugs that alter liver enzyme activity within 28 days prior to screening;
  8. Use of any prescription drugs, over-the-counter drugs, vitamin products or herbal medicines within 14 days prior to screening;
  9. Use of special diet (including dragon fruit, mango, grapefruit, etc.), strenuous activities or other factors that may affect the absorption, distribution, metabolism and excretion of the study drug within 2 weeks prior to screening;
  10. Concomitant use of strong inhibitors or inducers of CYP3A4, P-gp or Bcrp, such as itraconazole, ketoconazole or dronedarone;
  11. Subjects with major changes in diet or exercise habits recently;
  12. Use of study drugs or participation in other clinical trials within three months prior to dosing;
  13. Subjects who have ECG abnormalities with clinical significance;
  14. Subjects who have abnormalities with clinical significant in clinical laboratory tests or other clinical findings that indicate clinically significant diseases (including but not limited to gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric or cardiovascular diseases);
  15. Subjects with viral hepatitis (including hepatitis B and hepatitis C), AIDS antibody and/or antibody screening positive for Treponema pallidum;
  16. Subjects with acute disease or concomitant use of drugs from screening stage to dosing;
  17. Use of chocolate, food or beverages containing caffeine or xanthine within 24 hours prior to dosing;
  18. Use of products containing alcohol within 24 hours prior to dosing;
  19. Subjects with urine drug screening test positive, or with history of drug abuse in the past 5 years;
  20. Subjects with any other reasons that investigator considers to be unsuitable for the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03748745


Locations
Layout table for location information
China, Jilin
Phase I Clinical Trial Unit, The First Hospital of Jilin University
Changchun, Jilin, China, 130000
Sponsors and Collaborators
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Yanhua Ding, MD Phase I Clinical Trial Unit, The First Hospital of Jilin University
Layout table for additonal information
Responsible Party: Nanjing Sanhome Pharmaceutical, Co., Ltd.
ClinicalTrials.gov Identifier: NCT03748745    
Other Study ID Numbers: SHC005-I-04
First Posted: November 21, 2018    Key Record Dates
Last Update Posted: August 13, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Nanjing Sanhome Pharmaceutical, Co., Ltd.:
HCV
SH229